119 related articles for article (PubMed ID: 7867007)
41. Perillyl alcohol as a radio-/chemosensitizer in malignant glioma.
Rajesh D; Stenzel RA; Howard SP
J Biol Chem; 2003 Sep; 278(38):35968-78. PubMed ID: 12805388
[TBL] [Abstract][Full Text] [Related]
42. The presence of alpha 2u-globulin is necessary for d-limonene promotion of male rat kidney tumors.
Dietrich DR; Swenberg JA
Cancer Res; 1991 Jul; 51(13):3512-21. PubMed ID: 1711412
[TBL] [Abstract][Full Text] [Related]
43. Myrtenal ameliorates diethylnitrosamine-induced hepatocarcinogenesis through the activation of tumor suppressor protein p53 and regulation of lysosomal and mitochondrial enzymes.
Lingaiah HB; Natarajan N; Thamaraiselvan R; Srinivasan P; Periyasamy BM
Fundam Clin Pharmacol; 2013 Aug; 27(4):443-54. PubMed ID: 22436021
[TBL] [Abstract][Full Text] [Related]
44. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia.
Grasl-Kraupp B; Rossmanith W; Ruttkay-Nedecky B; Müllauer L; Kammerer B; Bursch W; Schulte-Hermann R
Hepatology; 1998 Sep; 28(3):717-26. PubMed ID: 9731564
[TBL] [Abstract][Full Text] [Related]
45. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor.
Raile K; Höflich A; Kessler U; Yang Y; Pfuender M; Blum WF; Kolb H; Schwarz HP; Kiess W
J Cell Physiol; 1994 Jun; 159(3):531-41. PubMed ID: 8188767
[TBL] [Abstract][Full Text] [Related]
46. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Stratton SP; Alberts DS; Einspahr JG; Sagerman PM; Warneke JA; Curiel-Lewandrowski C; Myrdal PB; Karlage KL; Nickoloff BJ; Brooks C; Saboda K; Yozwiak ML; Krutzsch MF; Hu C; Lluria-Prevatt M; Dong Z; Bowden GT; Bartels PH
Cancer Prev Res (Phila); 2010 Feb; 3(2):160-9. PubMed ID: 20103724
[TBL] [Abstract][Full Text] [Related]
47. Development of a perillyl alcohol topical cream formulation.
Gupta A; Myrdal PB
Int J Pharm; 2004 Jan; 269(2):373-83. PubMed ID: 14706249
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
Phillips LR; Malspeis L; Supko JG
Drug Metab Dispos; 1995 Jul; 23(7):676-80. PubMed ID: 7587953
[TBL] [Abstract][Full Text] [Related]
49. A new liver-tumor model in the rat.
Nagel JD; Kort WJ
Cancer Chemother Pharmacol; 1992; 30(1):70-2. PubMed ID: 1586983
[TBL] [Abstract][Full Text] [Related]
50. Clinical trials referral resource. Clinical trials with perillyl alcohol.
Zweibel J; Ho P; Sepelak SB; Saunders J; Cheson BD; Nelson A
Oncology (Williston Park); 1997 Dec; 11(12):1817, 1820. PubMed ID: 9436188
[No Abstract] [Full Text] [Related]
51. In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.
Andrade LN; Amaral RG; Dória GA; Fonseca CS; da Silva TK; Albuquerque Júnior RL; Thomazzi SM; do Nascimento LG; Carvalho AA; de Sousa DP
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26742032
[TBL] [Abstract][Full Text] [Related]
52. Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat.
Cini G; Coronnello M; Mini E; Neri B
Cancer Lett; 1998 Mar; 125(1-2):51-9. PubMed ID: 9566696
[TBL] [Abstract][Full Text] [Related]
53. Perillyl Alcohol (Monoterpene Alcohol), Limonene.
Shojaei S; Kiumarsi A; Moghadam AR; Alizadeh J; Marzban H; Ghavami S
Enzymes; 2014; 36():7-32. PubMed ID: 27102697
[TBL] [Abstract][Full Text] [Related]
54. Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display.
Ariazi EA; Gould MN
J Biol Chem; 1996 Nov; 271(46):29286-94. PubMed ID: 8910589
[TBL] [Abstract][Full Text] [Related]
55. Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol.
Fischer Jde S; Carvalho PC; Neves-Ferreira AG; da Fonseca CO; Perales J; Carvalho Mda G; Domont GB
J Exp Ther Oncol; 2008; 7(4):285-90. PubMed ID: 19227008
[TBL] [Abstract][Full Text] [Related]
56. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.
Chen TC; Fonseca CO; Schönthal AH
Am J Cancer Res; 2015; 5(5):1580-93. PubMed ID: 26175929
[TBL] [Abstract][Full Text] [Related]
57. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol.
Fischer Jde S; Liao L; Carvalho PC; Barbosa VC; Domont GB; Carvalho Mda G; Yates JR
J Proteomics; 2010 Mar; 73(5):1018-27. PubMed ID: 20083244
[TBL] [Abstract][Full Text] [Related]
58. Molecular pharmacology and therapeutic advances of monoterpene perillyl alcohol.
Zhang L; Wang G; Li Z; Yang J; Li H; Wang W; Li Z; Li H
Phytomedicine; 2024 Jun; 132():155826. PubMed ID: 38897045
[TBL] [Abstract][Full Text] [Related]
59. Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas.
da Fonseca CO; Khandelia H; Salazar MD; Schönthal AH; Meireles OC; Quirico-Santos T
Surg Neurol Int; 2016; 7():1. PubMed ID: 26862440
[TBL] [Abstract][Full Text] [Related]
60. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.
Chen TC; da Fonseca CO; Levin D; Schönthal AH
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
